Cargando…

Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer

Cardiotoxicity has been extensively reported in venlafaxine (VEN) overdoses. Asthenia is also among the common side effects described for this antidepressant. VEN is metabolized mainly by CYP2D6 and to a minor extent by CYP2C19 to the major active metabolite O-desmethylvenlafaxine (ODV). Altered pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia, Sofia, Schuh, Michael, Cheema, Anvir, Atwal, Herjot, Atwal, Paldeep S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662806/ https://www.ncbi.nlm.nih.gov/pubmed/29123929 http://dx.doi.org/10.1155/2017/6236714

Ejemplares similares

Case report: 5 year follow-up of adult late-onset mitochondrial encephalomyopathy with lactic acid and stroke-like episodes (MELAS)
por: Sunde, Kiri, et al.
Publicado: (2016)

CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial
por: Smith, D. Max, et al.
Publicado: (2019)

Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers
por: Chung, Woo Kyung, et al.
Publicado: (2022)

CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry
por: Molden, Espen, et al.
Publicado: (2021)

Maple syrup urine disease: mechanisms and management
por: Blackburn, Patrick R, et al.
Publicado: (2017)

Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites—a study in 839 patients with known CYP2D6 genotype
por: Wollmann, Birgit M., et al.
Publicado: (2023)

Co‐occurrence of a novel PDGFRB variant and likely pathogenic variant in CASR in an individual with extensive intracranial calcifications and hypocalcaemia
por: DeMeo, Natasha N., et al.
Publicado: (2017)

A novel splice site variant in CYP11A1 in trans with the p.E314K variant in a male patient with congenital adrenal insufficiency
por: Lara‐Velazquez, Montserrat, et al.
Publicado: (2017)

Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6‐Mediated Metabolic Activity
por: Dalton, Rachel, et al.
Publicado: (2019)

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
por: Ota, Tomoko, et al.
Publicado: (2015)

A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
por: Lee, Soo-Youn, et al.
Publicado: (2005)

Influence of the CYP2D6 Isoenzyme in Patients Treated with Venlafaxine for Major Depressive Disorder: Clinical and Economic Consequences
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Enantioselective metabolism of primaquine by human CYP2D6
por: Fasinu, Pius S, et al.
Publicado: (2014)

Modulation of CYP2D6 and CYP3A4 metabolic activities by Ferula asafetida resin
por: Al-Jenoobi, Fahad I., et al.
Publicado: (2014)

CYP2C19 and CYP2D6 Genotypes and Metabolizer Status Distribution in a Bulgarian Psychiatric Cohort
por: Ivanov, Hristo Y., et al.
Publicado: (2022)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
por: Bojić, Mirza, et al.
Publicado: (2019)

Case report: metoclopramide induced acute dystonic reaction in adolescent CYP2D6 poor metabolizers
por: Fink, Franz-Martin, et al.
Publicado: (2023)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
por: Lim, Sharoen Yu Ming, et al.
Publicado: (2022)

Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma
por: Khedhaier, Achraf, et al.
Publicado: (2008)

Hyponatremic Cognitive Dysfunction Resulting from Drug-Drug-Gene Interaction between Sertraline and Cannabidiol in an Intermediate CYP2C19 Metabolizer Patient
por: Nanan, Jade Camara, et al.
Publicado: (2022)

A sleep modulated Channelopathy: a novel CACNA1A pathogenic variant identified in episodic Ataxia type 2 and a potential link to sleep alleviated migraine
por: Ahuja, Abhimanyu S., et al.
Publicado: (2019)

Stress, Asthenia, and Cognitive Disorders
por: Vasenina, E. E., et al.
Publicado: (2023)

The Evaluation of CYP2D6, CYP2C9, CYP2C19, and CYP2B6 Phenoconversion in Post-Mortem Casework: The Challenge of Forensic Toxicogenetics
por: Giorgetti, Arianna, et al.
Publicado: (2023)

Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2?
por: Yasar, Umit
Publicado: (2018)

A Case Report of a Poor Metabolizer of CYP2D6 Presented with Unusual Responses to Nortriptyline Medication
por: Lee, Soo-Youn, et al.
Publicado: (2004)

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies
por: Li, Danyang, et al.
Publicado: (2023)

CYP2D6 Genotype Dependent Oxycodone Metabolism in Postoperative Patients
por: Stamer, Ulrike M., et al.
Publicado: (2013)

META-ANALYSIS OF CYP2D6 METABOLIZER PHENOTYPE AND METOPROLOL PHARMACOKINETICS
por: Blake, CM, et al.
Publicado: (2013)

The metabolism of primaquine to its active metabolite is dependent on CYP 2D6
por: Pybus, Brandon S, et al.
Publicado: (2013)

In vitro Assessment of the Effects of Silybin on CYP2B6-mediated Metabolism
por: Zhang, Wenwen, et al.
Publicado: (2023)

Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory
por: Varshney, Ekta, et al.
Publicado: (2012)

Additional Utility of Pharmacogenomics (PGx) Panel Testing in a CYP2D6 Normal Metabolizer with a History of Breast Cancer
por: Schuh, Michael J.
Publicado: (2019)

Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum
por: Decker, Brian S, et al.
Publicado: (2013)

Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice
por: Kapelyukh, Y., et al.
Publicado: (2019)

Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Carvalho Henriques, Beatriz, et al.
Publicado: (2021)

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
por: Wang, Jing, et al.
Publicado: (2018)

In Vitro and In Vivo Validation of CYP6A14 and CYP6N6 Participation in Deltamethrin Metabolic Resistance in Aedes albopictus
por: Peng, Hui, et al.
Publicado: (2023)

Patient with Marfan Syndrome and a Novel Variant in FBN1 Presenting with Bilateral Popliteal Artery Aneurysm
por: Mohammad, Ahmed, et al.
Publicado: (2018)

A complex case of delayed diagnosis of ornithine transcarbamylase deficiency in an adult patient with multiple comorbidities()
por: Abbott, Jessica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6hu3cvke9ebe9oujahja0fidjc